Literature DB >> 15740727

Effect of trazodone on hERG channel current and QT-interval.

Paul Tarantino1, Neal Appleton, Kate Lansdell.   

Abstract

Trazodone has been associated with prolonged QT-interval and increased risk of polymorphous ventricular tachycardias clinically and has demonstrated in vitro inhibition of hERG (human ether-á-go-go-related gene) channel current. This study attempts to put the effects of trazodone into perspective by comparing its hERG inhibition to that of three agents known to inhibit I(Kr), and comparing the effects of trazodone and cisapride on action potential duration and the QT-interval in the rabbit Langendorff heart preparation. Trazodone inhibited hERG channel current in a concentration-dependent manner with an IC50 of 0.69 microM. Like astemizole, terfenadine and cisapride, trazodone inhibits hERG channel current at clinically relevant concentrations. Like cisapride, trazodone increased both the QT-interval and APD90 in the Langendorff heart preparation in a reverse frequency-dependent manner at clinically relevant concentrations. These data strongly suggest that trazodone prolongs the QT-interval through inhibition of hERG channel current.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15740727     DOI: 10.1016/j.ejphar.2005.01.009

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Does your model weigh the same as a duck?

Authors:  Ajay N Jain; Ann E Cleves
Journal:  J Comput Aided Mol Des       Date:  2011-12-21       Impact factor: 3.686

2.  Reduction of repolarization reserve by halothane anaesthesia sensitizes the guinea-pig heart for drug-induced QT interval prolongation.

Authors:  Akira Takahara; Atsushi Sugiyama; Keitaro Hashimoto
Journal:  Br J Pharmacol       Date:  2005-10       Impact factor: 8.739

3.  Long-term bradycardia caused by atrioventricular block can remodel the canine heart to detect the histamine H1 blocker terfenadine-induced torsades de pointes arrhythmias.

Authors:  Akira Takahara; Atsushi Sugiyama; Yuko Ishida; Yoshioki Satoh; Kai Wang; Yuji Nakamura; Keitaro Hashimoto
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

4.  Inhibition of Kv4.3 potassium channels by trazodone.

Authors:  Yun Ju Chae; Jin-Sung Choi; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-25       Impact factor: 3.000

5.  Usefulness of Bnet, a Simple Linear Metric in Discerning Torsades De Pointes Risks in 28 CiPA Drugs.

Authors:  Sungpil Han; Seunghoon Han; Ki-Suk Kim; Hyang-Ae Lee; Dong-Seok Yim
Journal:  Front Pharmacol       Date:  2019-11-26       Impact factor: 5.810

Review 6.  Rediscovering trazodone for the treatment of major depressive disorder.

Authors:  Andrea Fagiolini; Alessandro Comandini; Mario Catena Dell'Osso; Siegfried Kasper
Journal:  CNS Drugs       Date:  2012-12       Impact factor: 5.749

7.  Assessing hERG pore models as templates for drug docking using published experimental constraints: the inactivated state in the context of drug block.

Authors:  Christopher E Dempsey; Dominic Wright; Charlotte K Colenso; Richard B Sessions; Jules C Hancox
Journal:  J Chem Inf Model       Date:  2014-02-06       Impact factor: 4.956

Review 8.  Pain medication and long QT syndrome.

Authors:  Christoph Klivinyi; Helmar Bornemann-Cimenti
Journal:  Korean J Pain       Date:  2018-01-02

9.  Pharmacokinetics, pharmacodynamics and clinical use of trazodone and its active metabolite m-chlorophenylpiperazine in the horse.

Authors:  J L Davis; J Schirmer; E Medlin
Journal:  J Vet Pharmacol Ther       Date:  2018-01-14       Impact factor: 1.786

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.